ATE226448T1 - Kombinationen von ileumgallensäuretransports inhibitoren und nicotinsäure derivaten für kardiovaskuläre indikationen - Google Patents
Kombinationen von ileumgallensäuretransports inhibitoren und nicotinsäure derivaten für kardiovaskuläre indikationenInfo
- Publication number
- ATE226448T1 ATE226448T1 AT99967141T AT99967141T ATE226448T1 AT E226448 T1 ATE226448 T1 AT E226448T1 AT 99967141 T AT99967141 T AT 99967141T AT 99967141 T AT99967141 T AT 99967141T AT E226448 T1 ATE226448 T1 AT E226448T1
- Authority
- AT
- Austria
- Prior art keywords
- ileumgallic
- combinations
- transport inhibitors
- cardiovascular indications
- acid derivatives
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11395598P | 1998-12-23 | 1998-12-23 | |
| US14255099P | 1999-07-07 | 1999-07-07 | |
| PCT/US1999/027950 WO2000038729A1 (en) | 1998-12-23 | 1999-12-17 | Combinations of ileal bile acid transport inhibitors and nicotinic acid derivatives for cardiovascular indications |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE226448T1 true ATE226448T1 (de) | 2002-11-15 |
Family
ID=26811675
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99967141T ATE226448T1 (de) | 1998-12-23 | 1999-12-17 | Kombinationen von ileumgallensäuretransports inhibitoren und nicotinsäure derivaten für kardiovaskuläre indikationen |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20030125316A1 (de) |
| EP (1) | EP1140191B1 (de) |
| JP (1) | JP2002533415A (de) |
| KR (1) | KR20010102963A (de) |
| CN (1) | CN1338946A (de) |
| AR (1) | AR037806A1 (de) |
| AT (1) | ATE226448T1 (de) |
| AU (1) | AU776952B2 (de) |
| BR (1) | BR9916567A (de) |
| CA (1) | CA2356664A1 (de) |
| CZ (1) | CZ20012343A3 (de) |
| DE (1) | DE69903661T2 (de) |
| DK (1) | DK1140191T3 (de) |
| EA (1) | EA005030B1 (de) |
| ES (1) | ES2188285T3 (de) |
| HK (1) | HK1044472A1 (de) |
| HU (1) | HUP0104593A3 (de) |
| IL (1) | IL143938A0 (de) |
| MX (1) | MXPA01006467A (de) |
| MY (1) | MY121399A (de) |
| NO (1) | NO20013160L (de) |
| NZ (1) | NZ512533A (de) |
| PL (1) | PL348581A1 (de) |
| PT (1) | PT1140191E (de) |
| WO (1) | WO2000038729A1 (de) |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0000772D0 (sv) | 2000-03-08 | 2000-03-08 | Astrazeneca Ab | Chemical compounds |
| US20020061888A1 (en) * | 2000-03-10 | 2002-05-23 | Keller Bradley T. | Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders |
| US6982251B2 (en) | 2000-12-20 | 2006-01-03 | Schering Corporation | Substituted 2-azetidinones useful as hypocholesterolemic agents |
| EG26979A (en) | 2000-12-21 | 2015-03-01 | Astrazeneca Ab | Chemical compounds |
| JP4711600B2 (ja) | 2001-01-26 | 2011-06-29 | シェーリング コーポレイション | シトステロール血症の処置のための置換アゼチジノン化合物の使用 |
| US7071181B2 (en) | 2001-01-26 | 2006-07-04 | Schering Corporation | Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors |
| SI1413331T1 (sl) | 2001-01-26 | 2008-02-29 | Schering Corp | Kombinacije fenofibrata peroksisomskega proliferator aktivirajocega receptorja (PPAR) z ezetimib zaviralcem absorpcije sterola za vaskularne indikacije |
| GB0121337D0 (en) | 2001-09-04 | 2001-10-24 | Astrazeneca Ab | Chemical compounds |
| GB0121622D0 (en) | 2001-09-07 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
| GB0121621D0 (en) | 2001-09-07 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
| MXPA04002179A (es) | 2001-09-08 | 2004-06-29 | Astrazeneca Ab | Derivados de benzotiazepina y benzotiadiazepina con actividad inhibidora de transporte del acido ileal biliar (ibat) para tratar hiperlipidemia. |
| US7132415B2 (en) | 2001-09-21 | 2006-11-07 | Schering Corporation | Methods and therapeutic combinations for the treatment of xanthoma using sterol absorption inhibitors |
| US7056906B2 (en) | 2001-09-21 | 2006-06-06 | Schering Corporation | Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women |
| US7053080B2 (en) | 2001-09-21 | 2006-05-30 | Schering Corporation | Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors |
| GB0209467D0 (en) | 2002-04-25 | 2002-06-05 | Astrazeneca Ab | Chemical compounds |
| GB0213669D0 (en) | 2002-06-14 | 2002-07-24 | Astrazeneca Ab | Chemical compounds |
| CA2504878A1 (en) | 2002-11-06 | 2004-05-27 | Schering Corporation | Cholesterol absorption inhibitors for the treatment of demyelination |
| GB0304194D0 (en) | 2003-02-25 | 2003-03-26 | Astrazeneca Ab | Chemical compounds |
| US7459442B2 (en) | 2003-03-07 | 2008-12-02 | Schering Corporation | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof |
| CN100439361C (zh) | 2003-03-07 | 2008-12-03 | 先灵公司 | 取代的2-吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途 |
| CN1756755A (zh) | 2003-03-07 | 2006-04-05 | 先灵公司 | 取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途 |
| JP4589919B2 (ja) | 2003-03-07 | 2010-12-01 | シェーリング コーポレイション | 高コレステロール血症の処置のための、置換アゼチジノン化合物、これらの処方物および使用 |
| GB0307918D0 (en) | 2003-04-05 | 2003-05-14 | Astrazeneca Ab | Therapeutic use |
| PL3400944T3 (pl) | 2010-11-04 | 2020-11-16 | Albireo Ab | Inhibitory ibat w leczeniu chorób wątroby |
| PT2637646T (pt) * | 2010-11-08 | 2016-08-17 | Albireo Ab | Uma combinação farmacêutica que compreende um inibidor do ibat e um sequestrador de ácido biliar |
| JP2012171911A (ja) | 2011-02-22 | 2012-09-10 | Kao Corp | Ｐｐａｒ活性化剤 |
| BR112014030835B1 (pt) * | 2012-06-15 | 2022-01-11 | Conaris Research Institute Ag | Composição contendo ácido nicotínico e/ou nicotinamida e/ou triptofano, e uso da mesma |
| JO3301B1 (ar) | 2013-04-26 | 2018-09-16 | Albireo Ab | تعديلات بلورية على إيلوبيكسيبات |
| KR102560954B1 (ko) | 2014-06-25 | 2023-07-31 | 이에이 파마 가부시키가이샤 | 고형 제제 및 그의 착색 방지 또는 착색 감소 방법 |
| TWI691331B (zh) | 2014-09-26 | 2020-04-21 | 日商興和股份有限公司 | 脂質異常症治療劑 |
| EP3012252A1 (de) | 2014-10-24 | 2016-04-27 | Ferring BV | Kristalline Form von elobixibat |
| CN108601745B (zh) | 2016-02-09 | 2021-12-07 | 阿尔比里奥公司 | 口服考来烯胺制剂及其用途 |
| ES2874669T3 (es) | 2016-02-09 | 2021-11-05 | Albireo Ab | Formulación oral de colestiramina y uso de la misma |
| US10441605B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US10441604B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Cholestyramine pellets and methods for preparation thereof |
| US10786529B2 (en) | 2016-02-09 | 2020-09-29 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| CN111032019B (zh) | 2017-08-09 | 2022-07-05 | 阿尔比里奥公司 | 考来烯胺颗粒、口服考来烯胺制剂及其用途 |
| WO2019032027A1 (en) | 2017-08-09 | 2019-02-14 | Albireo Ab | CHOLESTYRAMINE TABLETS, ORAL FORMULATIONS OF CHOLESTYRAMINE AND THEIR USE |
| US10793534B2 (en) | 2018-06-05 | 2020-10-06 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| EP3802504B1 (de) | 2018-06-05 | 2023-01-18 | Albireo AB | Benzothia(di)azepinverbindungen und ihre verwendung als gallensäuremodulatoren |
| EP3810084A1 (de) | 2018-06-20 | 2021-04-28 | Albireo AB | Pharmazeutische formulierung von odevixibat |
| US11801226B2 (en) | 2018-06-20 | 2023-10-31 | Albireo Ab | Pharmaceutical formulation of odevixibat |
| US11549878B2 (en) | 2018-08-09 | 2023-01-10 | Albireo Ab | In vitro method for determining the adsorbing capacity of an insoluble adsorbant |
| US10722457B2 (en) | 2018-08-09 | 2020-07-28 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US11007142B2 (en) | 2018-08-09 | 2021-05-18 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US10975045B2 (en) | 2019-02-06 | 2021-04-13 | Aibireo AB | Benzothiazepine compounds and their use as bile acid modulators |
| US10941127B2 (en) | 2019-02-06 | 2021-03-09 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
| DK3921028T3 (da) | 2019-02-06 | 2023-01-23 | Albireo Ab | Benzothiadiazepinforbindelser og anvendelse deraf som galdesyremodulatorer |
| CN118834175A (zh) | 2019-02-06 | 2024-10-25 | 阿尔比里奥公司 | 苯并硫氮杂环庚三烯化合物及其用作胆汁酸调节剂的用途 |
| CN114761018B (zh) | 2019-12-04 | 2025-12-02 | 阿尔比里奥公司 | 苯并硫杂二氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途 |
| WO2021110884A1 (en) | 2019-12-04 | 2021-06-10 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| US11014898B1 (en) | 2020-12-04 | 2021-05-25 | Albireo Ab | Benzothiazepine compounds and their use as bile acid modulators |
| DK4069360T3 (da) | 2019-12-04 | 2024-02-26 | Albireo Ab | Benzothia(di)azepinforbindelser og anvendelse deraf som galdesyremodulatorer |
| AR120674A1 (es) | 2019-12-04 | 2022-03-09 | Albireo Ab | Compuestos de benzotiazepina y su uso como ácido biliar |
| WO2021110886A1 (en) | 2019-12-04 | 2021-06-10 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| TWI877263B (zh) | 2019-12-04 | 2025-03-21 | 瑞典商艾爾比瑞歐公司 | 苯并噻二氮呯化合物及其作為膽酸調節劑之用途 |
| JP7696897B2 (ja) | 2019-12-04 | 2025-06-23 | アルビレオ・アクチボラグ | ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用 |
| PT4069360T (pt) | 2019-12-04 | 2024-03-06 | Albireo Ab | Compostos de benzotia(di)azepina e a sua utilização como moduladores de ácido biliar |
| ES2972045T3 (es) | 2019-12-04 | 2024-06-10 | Albireo Ab | Compuestos de benzotia(di)azepina y su uso como moduladores del ácido biliar |
| CN116157389B (zh) | 2020-08-03 | 2026-02-10 | 阿尔比里奥公司 | 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途 |
| JP2023549226A (ja) | 2020-11-12 | 2023-11-22 | アルビレオ エービー | 進行性家族性肝内胆汁うっ滞症（ｐｆｉｃ）を処置するためのオデビキシバット |
| WO2022117778A1 (en) | 2020-12-04 | 2022-06-09 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| TW202313579A (zh) | 2021-06-03 | 2023-04-01 | 瑞典商艾爾比瑞歐公司 | 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途 |
| AU2023285002A1 (en) | 2022-06-09 | 2024-12-05 | Albireo Ab | Treating hepatitis |
| WO2025146508A1 (en) | 2024-01-05 | 2025-07-10 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| WO2025146507A1 (en) | 2024-01-05 | 2025-07-10 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19916108C1 (de) * | 1999-04-09 | 2001-01-11 | Aventis Pharma Gmbh | Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung |
-
1999
- 1999-12-17 PL PL99348581A patent/PL348581A1/xx not_active Application Discontinuation
- 1999-12-17 DK DK99967141T patent/DK1140191T3/da active
- 1999-12-17 AT AT99967141T patent/ATE226448T1/de not_active IP Right Cessation
- 1999-12-17 ES ES99967141T patent/ES2188285T3/es not_active Expired - Lifetime
- 1999-12-17 EA EA200100703A patent/EA005030B1/ru not_active IP Right Cessation
- 1999-12-17 HK HK02106126.2A patent/HK1044472A1/zh unknown
- 1999-12-17 CZ CZ20012343A patent/CZ20012343A3/cs unknown
- 1999-12-17 HU HU0104593A patent/HUP0104593A3/hu unknown
- 1999-12-17 EP EP99967141A patent/EP1140191B1/de not_active Revoked
- 1999-12-17 NZ NZ512533A patent/NZ512533A/xx unknown
- 1999-12-17 CN CN99816327A patent/CN1338946A/zh active Pending
- 1999-12-17 JP JP2000590680A patent/JP2002533415A/ja active Pending
- 1999-12-17 IL IL14393899A patent/IL143938A0/xx unknown
- 1999-12-17 MX MXPA01006467A patent/MXPA01006467A/es not_active Application Discontinuation
- 1999-12-17 DE DE69903661T patent/DE69903661T2/de not_active Expired - Fee Related
- 1999-12-17 KR KR1020017008067A patent/KR20010102963A/ko not_active Withdrawn
- 1999-12-17 WO PCT/US1999/027950 patent/WO2000038729A1/en not_active Ceased
- 1999-12-17 AU AU23481/00A patent/AU776952B2/en not_active Ceased
- 1999-12-17 PT PT99967141T patent/PT1140191E/pt unknown
- 1999-12-17 BR BR9916567-8A patent/BR9916567A/pt not_active IP Right Cessation
- 1999-12-17 CA CA002356664A patent/CA2356664A1/en not_active Abandoned
- 1999-12-22 MY MYPI99005678A patent/MY121399A/en unknown
- 1999-12-23 AR ARP990106755A patent/AR037806A1/es unknown
-
2001
- 2001-06-22 NO NO20013160A patent/NO20013160L/no not_active Application Discontinuation
-
2002
- 2002-09-18 US US10/245,507 patent/US20030125316A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| DE69903661D1 (de) | 2002-11-28 |
| IL143938A0 (en) | 2002-04-21 |
| EP1140191B1 (de) | 2002-10-23 |
| US20030125316A1 (en) | 2003-07-03 |
| NZ512533A (en) | 2004-02-27 |
| JP2002533415A (ja) | 2002-10-08 |
| WO2000038729A1 (en) | 2000-07-06 |
| EA005030B1 (ru) | 2004-10-28 |
| CZ20012343A3 (cs) | 2001-12-12 |
| CN1338946A (zh) | 2002-03-06 |
| KR20010102963A (ko) | 2001-11-17 |
| EA200100703A1 (ru) | 2001-12-24 |
| HUP0104593A2 (hu) | 2002-03-28 |
| AU776952B2 (en) | 2004-09-30 |
| PT1140191E (pt) | 2003-01-31 |
| DE69903661T2 (de) | 2003-07-03 |
| ES2188285T3 (es) | 2003-06-16 |
| EP1140191A1 (de) | 2001-10-10 |
| MXPA01006467A (es) | 2004-03-10 |
| NO20013160D0 (no) | 2001-06-22 |
| DK1140191T3 (da) | 2003-02-24 |
| HK1044472A1 (zh) | 2002-10-25 |
| PL348581A1 (en) | 2002-06-03 |
| AR037806A1 (es) | 2004-12-09 |
| MY121399A (en) | 2006-01-28 |
| CA2356664A1 (en) | 2000-07-06 |
| HUP0104593A3 (en) | 2004-10-28 |
| NO20013160L (no) | 2001-08-21 |
| BR9916567A (pt) | 2001-12-11 |
| AU2348100A (en) | 2000-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE226448T1 (de) | Kombinationen von ileumgallensäuretransports inhibitoren und nicotinsäure derivaten für kardiovaskuläre indikationen | |
| ATE240120T1 (de) | Kombinationen von ileumgallensäuretransports inhibitoren und fibronsäure derivaten für kardiovaskuläre indikationen | |
| ATE228012T1 (de) | Kombinationen von ileumgallensäuretransports inhibitoren und gallensäure sequestriermitteln für kardiovaskuläre indikationen | |
| NO20014823D0 (no) | Heterocyklus-holdige bifenyl-aP2-inhibitorer og metode | |
| ATE417828T1 (de) | Heterocyclische inhibitoren von p38 | |
| DE60032469D1 (de) | Verfahren und anordnung für zuverlässige übertragung von datenpaketen | |
| DK0958277T3 (da) | Inhibitorer for nitrogenmonoxidsyntase | |
| DK0934301T3 (da) | Aminothiophencarboxylsyreamider og anvendelse deraf som phosphodiesteraseinhibitorer | |
| EE9700182A (et) | Mikrosoomse triglütseriidi transportproteiini inhibiitorid ja meetod | |
| DK1114051T3 (da) | Inhibitorer for p38 | |
| ATE231883T1 (de) | Neuartige aminosäurederivate und deren verwendung als thrombininhibitoren | |
| NO982176D0 (no) | Korrosjonsinhiberte organiske syresammensetninger og fremgangsmÕter for anvendelse av disse | |
| DE60029947D1 (de) | System und verfahren für joint-time-tracking von mehrfachen pfaden | |
| DE69922399D1 (de) | Gefrierschutzzusammensetzungen, carbonsäure- und cyclohexensäure-korrosionsinhibitoren enthaltend | |
| FI19991896L (fi) | Nikotiinihappokoostumuksia hyperlipemian hoitamiseksi ja vastaavia menetelmiä | |
| DE69939417D1 (de) | In-Line Inspektion von Behältern | |
| IS5582A (is) | Meta-asahringamínóbensósýrusambönd og afleiður þeirra reynast mótlyf við integríni. | |
| DE69523009D1 (de) | Schaltungsstruktur und Verfahren zur Belastungsprüfung von Bitleitungen | |
| DE60016629D1 (de) | Ox(adi)azoly-hydroxamsäuren und ihre verwendung als prokollagen c-proteinase inhibitoren | |
| DE59906848D1 (de) | Markierungsverfahren von Messspuren | |
| NO982177D0 (no) | Metallkorrosjonsinhiberte organiske syresammensetninger og fremgangsmÕter for anvendelse av disse | |
| ATE303995T1 (de) | Substituierte phenylcyclohexancarbonsäureamide und ihre verwendung als adenosinaufnahme- inhibitoren | |
| EP1242080A4 (de) | Inhibitoren von dopaminetransport und deren verwendung | |
| DK1115389T3 (da) | Fructosamin-oxidase: antagonister og inhibitorer | |
| NO20001447D0 (no) | Modifisert polyasparginsyre og fremgangsmåte for produksjon og bruk derav |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1140191 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee | ||
| RZN | Patent revoked |